A phase II exploratory open-label study of recombinant human C1 inhibitor for the treatment of acute attacks of hereditary angioedema

被引：0
|
作者：
Choi, G
Soeters, M
Verdonk, R
van Dam, T
Nuijens, J
Hack, CE
Levi, M
机构：
[1] Univ Amsterdam, Acad Med Ctr, Dept Internal Med, NL-1105 AZ Amsterdam, Netherlands
[2] Pharming Grp NV, Leiden, Netherlands
[3] Sanquin Res, Dept Immunopathol, Asmera, Eritrea
来源：
MOLECULAR IMMUNOLOGY | 2004年 / 41卷 / 2-3期
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
40
引用
收藏
页码：220 / 220
页数：1
相关论文
共 50 条
  • [41] Clinical studies of recombinant human C1 inhibitor (rhC1INH) in patients with acute attacks of hereditary angioedema
    Nuijens, J.
    Verdonk, R.
    Giannetti, B.
    Visscher, S.
    van Doorn, M.
    Resink, T.
    Levi, M.
    Hack, C.
    Farkas, H.
    Obtulowicz, K.
    Caballero, T.
    Cicardi, M.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2008, 121 (03) : 797 - 797
  • [42] C1 esterase inhibitor (C1-INH) concentrate in the treatment of acute attacks of hereditary angioedema: interim results of the treatment of 789 attacks in an ongoing, prospective, open-label study in North America (IMPACT2)
    Levy, R.
    Wasserman, R.
    Bewtra, A.
    Hurewitz, D.
    Moy, J.
    Yang, W.
    Schneider, L.
    Packer, F.
    Bahna, S.
    Jacobson, K.
    Offenberger, J.
    Eidelmann, F.
    Janss, G.
    Kiessling, P.
    Peters, C.
    Craig, T.
    ALLERGY, 2009, 64 : 154 - 154
  • [43] C1 Esterase Inhibitor (C1-INH) Concentrate in the Treatment of Acute Attacks in Hereditary Angioedema: Interim Results of the Treatment of 975 Attacks in an Ongoing, Prospective, Open-Label Study in North America (IMPACT2)
    Goodman, S.
    Levy, R.
    Wasserman, R.
    Bewtra, A.
    Hurewitz, D.
    Moy, J.
    Yang, W.
    Schneider, L.
    Packer, F.
    Bahna, S.
    Jacobson, K.
    Offenberger, J.
    Eidelman, F.
    Janss, G.
    Kiessling, P.
    Peters, C.
    Craig, T.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2010, 125 (02) : AB166 - AB166
  • [44] Recombinant and Plasma-Purified Human C1 Inhibitor for the Treatment of Hereditary Angioedema
    Frank, Michael M.
    WORLD ALLERGY ORGANIZATION JOURNAL, 2010, 3 : S29 - S33
  • [45] A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema (HAE)
    van Doorn, MBA
    Nuijens, J
    van Dam, T
    Levi, M
    Hack, E
    Cohen, AF
    Burggraaf, J
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 59 (01) : 136 - 136
  • [46] Recombinant human C1-inhibitor in the treatment of acute angioedema attacks
    Choi, Goda
    Soeters, Maarten R.
    Farkas, Henriette
    Varga, Lilian
    Obtulowicz, Krystyna
    Bilo, Barbara
    Porebski, Greg
    Hack, C. Erik
    Verdonk, Rene
    Nuijens, Jan
    Levi, Marcel
    TRANSFUSION, 2007, 47 (06) : 1028 - 1032
  • [47] Recombinant Human C1 Esterase Inhibitor in the Management of Hereditary Angioedema
    Marc Riedl
    Clinical Drug Investigation, 2015, 35 : 407 - 417
  • [48] Recombinant Human C1 Esterase Inhibitor in the Management of Hereditary Angioedema
    Riedl, Marc
    CLINICAL DRUG INVESTIGATION, 2015, 35 (07) : 407 - 417
  • [49] Pharmacokinetics of Subcutaneous C1 Esterase Inhibitor (human) with Recombinant Human Hyaluronidase for the Prevention of Angioedema Attacks in Patients with Hereditary Angioedema
    Lumry, William R.
    Li, H. Henry
    Magerl, Markus
    Maurer, Marcus
    Bernstein, Jonathan A.
    Riedl, Marc A.
    Bas, Murat
    Banerji, Aleena
    Rockich, Kevin
    Schranz, Jennifer
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2015, 135 (02) : AB192 - AB192
  • [50] The prophylaxis of hereditary angioedema attacks with recombinant human C1 inhibitor: who will take advantage of the individualized treatment approach?
    Porebski, G.
    ALLERGY, 2013, 68 (09) : 1207 - 1207
12345